142 related articles for article (PubMed ID: 16847424)
1. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.
Schneider S; Park DJ; Yang D; El-Khoueiry A; Sherrod A; Groshen S; Streeter O; Iqbal S; Danenberg KD; Lenz HJ
Pharmacogenet Genomics; 2006 Aug; 16(8):555-63. PubMed ID: 16847424
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
3. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer.
Yang D; Schneider S; Azuma M; Iqbal S; El-Khoueiry A; Groshen S; Agafitei D; Danenberg KD; Danenberg PV; Ladner RD; Lenz HJ
Clin Colorectal Cancer; 2006 Nov; 6(4):305-11. PubMed ID: 17241515
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.
Zhang W; Park DJ; Lu B; Yang DY; Gordon M; Groshen S; Yun J; Press OA; Vallböhmer D; Rhodes K; Lenz HJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):600-5. PubMed ID: 15701846
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
8. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
Stoehlmacher J; Goekkurt E; Mogck U; Aust DE; Kramer M; Baretton GB; Liersch T; Ehninger G; Jakob C
Cancer Lett; 2008 Dec; 272(2):221-5. PubMed ID: 18722050
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE
Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer.
Kim JW; Kim YB; Choi JJ; Koom WS; Kim H; Kim NK; Ahn JB; Lee I; Cho JH; Keum KC
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):e577-84. PubMed ID: 22981710
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region.
Spindler KL; Nielsen JN; Lindebjerg J; Brandslund I; Jakobsen A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):500-4. PubMed ID: 16757132
[TBL] [Abstract][Full Text] [Related]
16. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
Spindler KL; Nielsen JN; Lindebjerg J; Jakobsen A
Dis Colon Rectum; 2007 Sep; 50(9):1363-9. PubMed ID: 17661145
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
18. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience.
Asoglu O; Karanlik H; Muslumanoglu M; Igci A; Emek E; Ozmen V; Kecer M; Parlak M; Kapran Y
Eur J Surg Oncol; 2007 Dec; 33(10):1199-206. PubMed ID: 17400423
[TBL] [Abstract][Full Text] [Related]
20. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.
Tateishi Y; Tatemoto Y; Ohno S; Morishita K; Ueta E; Yamamoto T
Cancer Lett; 2009 Feb; 274(2):187-93. PubMed ID: 18986760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
